Experimental evaluation of the NeVa™ thrombectomy device: a novel stent retriever conceived to improve efficacy of organized clot removal

Paolo Machi a,*, Arthur J. Ulm b, Gianmarco Bernava a, Olivier Brina a, Karl Olof Lovblad a, Franck Jourdan c

a University Hospital of Geneva, Switzerland
b Nashville Neurosurgery Associates, Nashville, TN, USA
c Department of Mechanical Engineering, University of Montpellier, France

A B S T R A C T

Background and purpose. – Stent retrievers are recognized as the most effective devices for intracranial thrombectomy. Although highly effective, such devices fail in clot removal when the brain vessel occlusion is due to organized, firm clots. The mechanism of failure is that during the retrieval, devices remain compressed by the organized clot and slide between it and the vessel wall without any removal effect. The aim of the current study is to present the preclinical evaluation of the NeVa™ device, a novel stent retriever designed to improve the incorporation and removal of organized thrombi.

Materials and methods. – Preclinical evaluation of the NeVa™ device was divided in three main chapters: efficacy analysis, mechanical analysis and safety analysis. Efficacy and mechanical analysis aimed to investigate the behavior during the retrieval of the NeVa™ device and its interaction with experimental organized clots. Safety analysis was conducted on animals in order to investigate the effect of the NeVa™ device on real arteries after simulated thrombectomy maneuvers.

Results. – NeVa™ device showed a high rate of “optimal clot integration” and “effective clot removal” which was related to constant cohesion to the vessel wall during retrievals. Safety analysis showed as the most frequent finding the disruption of the intima of the tested vessels with, in some cases, minimal disruption of the internal elastic lamina.

Conclusions. – The NeVa™ device has demonstrated safety and efficacy in a pre-clinical study. Such encouraging, preliminary results have to be compared with those of clinical trials.

Introduction

A number of trials demonstrated that stent retriever based MTB is a safe and effective treatment for acute ischemic stroke. Successful artery recanalization rates range between 58% and 88% [1–5]. Nevertheless, in a relatively high percentage of cases (up to 42%) stent retrievers fail in clot removal. One possible source of treatment failure is organized, firm clots. The mechanism of failure is that during the retrieval, devices remain compressed by the organized clots and slide between the clot and the vessel wall without any removal effect [6]. The aim of the current study is to present the preclinical evaluation of the NeVa™ device, a novel stent retriever designed to improve the incorporation and removal of organized thrombi. The novel feature of the NeVa™ devices is the presence of offset drop zones which allow for the incorporation of organized clot to the inside of the device during retrieval.

Abbreviations: MTB, mechanical thrombectomy; MCA, middle cerebral artery; ACA, anterior cerebral artery; ICA, internal carotid artery; OCI, optimal clot integration; NOCI, not optimal clot integration; ECR, effective clot removal; NECR, not effective clot removal; DSA, digital subtracted angiography.

* Corresponding author at: Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4, CH-1205 Geneva, Switzerland.
E-mail address: Paolo.Machi@hcuge.ch (P. Machi).

Materials and methods

Description of the NeVa™ device

The device comes in two sizes for site-specific deployment: NeVa™ T and NeVa™ M1 (Fig. 1). There are five zones along the devices. From proximal to distal: flow restoration zone, first drop...
zone, inter-drop zone support cell, second drop zone and distal capture basket. These structural zones correspond with radial force and function. The proximal portion of the device acts as a common stent retriever compressing the thrombus toward vessel wall and re-establishing some flow within the artery (by-pass effect). The drop zones are perpendicular to each other, such configuration provide a 360° entry area to improve the likelihood of clot capture. Radiopaque markers are located at the edge of the drop zones and allow the optimal deployment regarding the interaction clot/device. The distal portion of the device is closed ended and functions as a capture basket designed to reduce distal embolization during retrieval. NevaT™ T measures 4.5 mm in diameter and 44 mm in length and NevaT™ M1 measures 4.0 mm in diameter and 36 mm in length; both devices are 0.021 in microcatheter compatible.

Efficacy analysis

Organized clot removal efficacy and device behavior during retrieval were evaluated while performing experimental thrombectomies using a vascular phantom and organized clot homologues. Experiments were performed under fluoroscopy using a bi-plane angiography system (Allura FD 20, Philips Healthcare, Best, Netherlands). A high definition video camera simultaneously filming experiments was used for double control. Procedures were performed by two neurointerventionalists with experience in MTB (PM, GB).

Vascular phantom

Tests were performed using a 3D printed vascular model made by stereolithography with a translucent photosensitive resin reproducing the MCA, the ACA and the ICA. The diameter of the MCA was 2.5 mm, the diameter of the ICA varied from 3 to 6 mm (from distal to proximal) (Fig. 2). The phantom was continuously flushed by a gear pump injecting water heated to 37°C to simulate the in vivo expansion temperature of the nitinol devices.

Clot model

Organized clot homologues were produced with human blood; five healthy volunteers without history of medication use consented to provide blood samples for the study. Organized clots were produced with platelet-rich plasma. It was extracted from whole blood after centrifugation at 350 g for 10 min at 22°C. Hence, platelet-rich plasma was incubated at 37°C for 1 h and thereafter organized clots were extracted [7–9]. Clots were produced in diameters of 4 mm (middle) and 6 mm (large).
Experimental thrombectomies

The interaction of the device with the organized thrombus and the behavior of the device during retrieval were evaluated using fluoroscopy and magnified video imaging. Organized clots of 4 and 6 mm in diameter were delivered within the MCA or the terminal ICA of the phantom respectively. For the evaluation of Neva™ T the clot was delivered at terminal ICA while for Neva™ M1 the clot was delivered at M1. Procedures were performed using standard technique via a 6F-guiding catheter connected to the phantom [8]. For both devices the aim was to evaluate whether the drop zones were a point of capture of the clot and whether the operator could influence clot integration by performing a succession of pull and release maneuvers guided by the markers located at the leading edge of the drop zones oriented 90° offset relative to each other (Fig. 1). No anterograde flow arrest or concomitant aspiration were performed during the retrievals. For each thrombectomy procedure, operators performed up to three passes and ten thrombectomies were performed for each device. Results were scored as follows: optimal clot integration (OCI: when clots entered the drop zones)/not optimal clot integration (NOCI), effective clot removal (ECR; when clots were completely removed from the phantom)/not effective clot removal (NECR).

Mechanical analysis

Mechanical analysis aimed to evaluate the radial force variation of Neva™ devices during the retrieval. Such measurements were performed by Pull up traction tests [9]. For these tests, devices were deployed within silicon tubes of different diameters (1.5 mm and 3 mm) and the delivery wires were connected to the traction transducer arm of a tensile test machine. The traction arm retrieved the devices for 5 mm at a velocity of 2 mm/s. Each stent was tested 5 times and the average value of the force exerted by the machine during the retrieval was used to calculate the radial pressure of the device over the tube wall, these values were expressed in Pascal (Newton/m²).

Safety analysis

Such analysis was conducted on animals in order to investigate the effect of Neva™ devices on real arteries after simulated thrombectomy maneuvers. Procedures were performed in accordance with lab standard operating procedures and ethical guidelines of the institutional animal care committee. Three swine were employed for the study. The procedures were performed under DSA guidance. Each device was tested in two branches of the external carotid artery in the following manner: vessels were selected with a standard 0.021 in. microcatheter; hence, the Neva™ device was deployed in the vessel and re-sheathed into the microcatheter using a combination of pushing the catheter while pulling the device. The device was deployed and re-sheathed three times after which it was deployed a fourth time and a complete retrieval performed by dragging the device from the study vessel into a 6F guide-catheter placed in the common carotid artery. The test was repeated with the same device in a second vessel in an identical manner. Pre and post deployment/retrieval angiograms were performed and a quantitative assessment of vasospasm was performed using the GE segment analysis software (Fig. 3). According to Grandin’ classification [10] vasospasm was graded as follows: mild = vessel diameter reduction of ≤25%, moderate = vessel diameter reduction of 25–50% (or 50–75% for a focal segment), severe = vessel diameter reduction of 50–75% (or >75% for a focal segment). Furthermore, angiographic images were evaluated for the presence of complications including vessel perforation, extravasation or dissection. After testing, animals were euthanized and the study branches as well as control vessels (lingual arteries) were examined for evidence of gross injury and then harvested and sent to an independent laboratory for histopathological examination. In order to assess the degree of arterial injury a semiquantitative analysis of histopathologic changes of the tested vessel was conducted [11]. For such analysis the following parameters were recorded: endothelial loss, presence of platelet or fibrin on the luminal surface, hemorrhage in the media and/or in the adventitia, medial injury. These parameters were used to calculate a score ranging form 0 (no vessel injury) to 20 (highest degree of injury) (Table 1).

Results

Efficacy analysis

Results of experimental thrombectomies are reported in (Table 2). Neva™ M1 demonstrated the highest rate of OCI which was related to ECR (n = 7 out of 10). Neva™ T showed similar overall rate of ECR (n = 7 out of 10) although in one case the clot was not integrated into the device but remained engaged within the stent struts during the retrieval. The average number of passes for Neva™ M1 was 1.8 while for Neva™ T it was 1.9. Both devices maintained constant adhesion to the vessel wall during retrievals. In addition, when retrieved over sharp angles of the rigid vascular phantom, the devices showed limited elongation. This was due to the design of the device. The Drop zones divide the device into five separate compartments (Fig. 1). When retrieved over a sharp angle, the proximal compartment (“flow restoration zone”) initially
retrievers in tubes of 1.5 and 3.5 mm of diameter. Values were measured by radial force. The lower value was recorded for both devices in tubes of 1.5 mm and 3.5 mm respectively. All devices showed significant shift when devices were retrieved in tubes of different diameters, elongates but beyond the angle promptly re-expands. The ability to re-expand and regain adhesion to the wall is due to the fact that the segments of the device are connected by parallel and offset thin linear struts that do not transmit the tangential friction exerted by the angle during the retrieval. Such behavior allowed for constant cohesion to the vessel wall during retrievals. Maintaining wall apposition has been shown to be a factor that improves the efficacy of clot removal [12,13].

**Mechanical analysis**

The purpose of the test was to determine the radial force shift when devices were retrieved in tubes of different diameters, 1.5 mm and 3.5 mm respectively. All devices showed significant reduction of the radial force with NevaTM M1 having a 30% reduction of radial force and NevaTM T demonstrating a 42% reduction in radial force. The lower value was recorded for both devices in tubes of 3.5 mm, but in each case the radial force was higher than 853 Pa (N/m²) (Table 3).

**Safety analysis**

For such analysis a total of six vessels from three animals were evaluated. After repeated maneuvers of devices deployment, re-sheathing and retrieving (reported above) all vessels showed vasoconstriction just after stent retrieval (first 10 min). Recovery of the vasoconstriction (complete or <10%) was recorded at 60 min after the experimental procedures. No vessel perforations or dissections were observed on per-procedural DSA controls. Pathology showed no swelling, bruising or perforation of the treated vessels. Histology found different degrees of endothelial loss for all examined vessels. A focal lesion of the internal elastic lamina was recorded in one case for NevaTM M1. Medial hemorrhage or thrombus formation were not found in the examined samples. Injury scores ranged from 2.63 to 2.88 (out of 20); the most common finding was endothelial loss.

**Discussion**

Efficacy of clot removal is due to the interaction between the stent retriever and the clot. Depending on the degree of the migration of the stent struts into the clot after deployment, the clot is completely integrated, partially penetrated by the struts or remains outside the stent. Clot removal failure is usually due to the presence of an organized large, clot. In such instance the stent does not penetrate the clot, but remains compressed between the clot and the vessel wall and during the retrieval, the device slides beside it without retrieving it [14–19]. The penetration of the struts within the clot is promoted by device radial force and large openings between device filaments [20]. We report on pre-clinical data related to the safety and efficacy of the NevaTM platform of thrombectomy devices, which were engineered to improve interaction with organized clot. The main difference in comparison with currently available stent retrievers is the presence of drop zones that are enlarged openings within the device allowing for the lateral integration of the clots. Radiopaque markers located just proximal to the drop zones, allows the operator to mentally see the interaction of the device with the clot, particularly when clot is externally compressing the device at the interface. In such cases, the operator can maneuver by gently pulling and releasing the delivery guidewire to effect micromovement of the retriever in order to facilitate internal capture of external organized thrombus identified by an opening of the markers.

The markers placed at the leading edge of them identify drop zones. When the stent is retrieved over the clot the markers are compressed and pushed together and are identifiable as a single point, in such a configuration the device is constrained and the drop zones are closed and the clot cannot entry through them. In order to allow the drop zones to open, the operator has to release tension on the push wire until the device expands so the opening of the
drop zones is identified by the separation of the proximal markers. The operator must not perform a pushing movement because markers pushed toward the vessel wall could damage the endothelium, instead a succession of tension (pulling) and release cycles are repeated until the markers open and the device is pulled proximally.

We divided our preclinical evaluation in three main chapters: efficacy analysis, mechanical analysis and safety analysis. Efficacy analysis permitted the visualization of the drop zones incorporating the firm clot and capturing the clot in the distal closed end. Considering that Experimental thrombectomies were performed using organized, firm clots, the overall rate of OCT and ECR has to be compared with those of clinical trials to determine if this novel device improves upon current stent retriever outcomes in the treatment of acute ischemic stroke. Some degree of vasospasm was noted during experiments; in all cases it recovered fully or to less than 10% on serial controls performed for 30–60 min after final retrieval.

In summary, the Neva™ device has demonstrated safety and efficacy in a pre-clinical study. Such encouraging, preliminary results have to be compared with those of clinical trials to determine if this novel device improves upon current stent retriever outcomes in the treatment of acute ischemic stroke.

Disclosure of interest
Legacy Ventures funded this project; however, all the performance data analysis and interpretation was performed by the authors, independent of Legacy Ventures’s input or interpretation. Jay Ulm has stock ownership in Legacy Ventures.

References
[18] Jay Ulm has stock ownership in Legacy Ventures.

Table 4
Adapted from the publication of Machi et al. [9], results of experimental thrombectomy performed with currently available stent retrievers in a similar study with white experimental clots produced with the same protocol.

<table>
<thead>
<tr>
<th>Device</th>
<th>Size</th>
<th>Large white clot</th>
<th>Medium white clot</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trevo PV</td>
<td>4–20</td>
<td>0/5</td>
<td>2/5</td>
<td>0–33%</td>
</tr>
<tr>
<td>Eric</td>
<td>3–20</td>
<td>0/5</td>
<td>1/5</td>
<td>0–20%</td>
</tr>
<tr>
<td>6–44</td>
<td>0/5</td>
<td>3/5</td>
<td>0–60%</td>
<td></td>
</tr>
<tr>
<td>Embobtrap</td>
<td>5–21</td>
<td>1/5</td>
<td>2/5</td>
<td>20–40%</td>
</tr>
<tr>
<td>Penumbra 3D</td>
<td>4.5–26</td>
<td>0/5</td>
<td>2/5</td>
<td>0–40%</td>
</tr>
<tr>
<td>Revive</td>
<td>4.5–22</td>
<td>1/5</td>
<td>2/5</td>
<td>20–40%</td>
</tr>
<tr>
<td>Mindframe</td>
<td>3–23</td>
<td>0/5</td>
<td>2/5</td>
<td>0–40%</td>
</tr>
<tr>
<td>Solitaire FR</td>
<td>4–20</td>
<td>0/5</td>
<td>3/5</td>
<td>0–60%</td>
</tr>
<tr>
<td>6–30</td>
<td>1/5</td>
<td>3/5</td>
<td>20–60%</td>
<td></td>
</tr>
<tr>
<td>Preset</td>
<td>4–20</td>
<td>0/5</td>
<td>3/5</td>
<td>0–60%</td>
</tr>
<tr>
<td>6–30</td>
<td>2/5</td>
<td>3/5</td>
<td>40–60%</td>
<td></td>
</tr>
<tr>
<td>Preset LT</td>
<td>3–20</td>
<td>0/5</td>
<td>1/5</td>
<td>0–20%</td>
</tr>
<tr>
<td>4–20</td>
<td>0/5</td>
<td>2/5</td>
<td>0–40%</td>
<td></td>
</tr>
<tr>
<td>Catch</td>
<td>3–15</td>
<td>1/5</td>
<td>1/5</td>
<td>0–20%</td>
</tr>
<tr>
<td>4–20</td>
<td>1/5</td>
<td>1/5</td>
<td>0–20%</td>
<td></td>
</tr>
<tr>
<td>6–30</td>
<td>1/5</td>
<td>3/5</td>
<td>20–60%</td>
<td></td>
</tr>
<tr>
<td>Neva™ M1</td>
<td>4–36</td>
<td>NA</td>
<td>7/10</td>
<td>70%</td>
</tr>
<tr>
<td>Neva™ T</td>
<td>4.5–44</td>
<td>6/10</td>
<td>NA</td>
<td>60%</td>
</tr>
</tbody>
</table>

* Minimal clot displacement.